drugset / Trial / NCT01166698

Single Centre, Double-blind, Single and Multiple Ascending Inhaled Doses of AZD9819 in Healthy Subjects

NCT01166698 ↗

Phase 1 Completed 100 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of the study is to assess safety and tolerability of AZD9819 following inhaled administration of single and multiple increasing doses, and to estimate the maximum dose that is tolerated in healthy people.

Timeline

Start
2010-08
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject AZD9819 Unknown — Inhaled

Indications

No indication recorded.